Neurocrine Biosciences Inc (NBIX) Insider Trading
- $39,032,821.44
- $380,590,314.37
- Feb. 13, 2025
- Kevin Charles Gorman
| Trader Name | Date | Title | Amount | Price | Type | Total Value |
|---|---|---|---|---|---|---|
| Feb. 13, 2025 | CFO | 2,558 | $116.86 | Sell | $298,927.88 | |
| Feb. 13, 2025 | Director | 5,844 | $116.69 | Sell | $681,936.36 | |
| Feb. 13, 2025 | Insider | 1,551 | $116.78 | Sell | $181,125.78 | |
| Feb. 10, 2025 | Insider | 700 | $118.28 | Sell | $82,796.00 | |
| Feb. 10, 2025 | Director | 2,274 | $118.37 | Sell | $269,173.38 | |
| Feb. 10, 2025 | CEO | 980 | $118.39 | Sell | $116,022.20 | |
| Feb. 3, 2025 | Insider | 623 | $149.29 | Sell | $93,007.67 | |
| Jan. 31, 2025 | CEO | 1,541 | $152.87 | Sell | $235,572.67 | |
| Jan. 31, 2025 | CFO | 1,283 | $152.87 | Sell | $196,132.21 | |
| Jan. 31, 2025 | Insider | 1,740 | $152.89 | Sell | $266,028.60 | |
| Jan. 31, 2025 | Director | 2,707 | $152.92 | Sell | $413,954.44 | |
| Jan. 27, 2025 | Director | 146,105 | $149.46 | Sell | $21,836,853.30 | |
| Jan. 15, 2025 | CEO | 65,000 | $141.50 | Sell | $9,197,500.00 | |
| Dec. 31, 2024 | Insider | 272 | $138.10 | Sell | $37,563.20 | |
| Dec. 17, 2024 | Insider | 1,091 | $135.00 | Sell | $147,285.00 | |
| Nov. 29, 2024 | Insider | 2,331 | $126.29 | Sell | $294,381.99 | |
| Aug. 15, 2024 | Director | 14,250 | $146.69 | Sell | $2,090,332.50 | |
| Aug. 13, 2024 | Insider | 7,143 | $150.10 | Sell | $1,072,164.30 | |
| Aug. 13, 2024 | Director | 11,570 | $150.43 | Sell | $1,740,475.10 | |
| Aug. 13, 2024 | CFO | 14,100 | $150.38 | Sell | $2,120,358.00 | |
| Aug. 6, 2024 | Insider | 273 | $147.70 | Sell | $40,322.10 | |
| Aug. 1, 2024 | Insider | 12,632 | $153.26 | Sell | $1,935,980.32 | |
| July 16, 2024 | Insider | 900 | $150.04 | Sell | $135,036.00 | |
| July 16, 2024 | Director | 930 | $150.03 | Sell | $139,527.90 | |
| July 1, 2024 | Insider | 10,000 | $140.19 | Sell | $1,401,900.00 | |
| May 29, 2024 | Director | 40,000 | $133.46 | Sell | $5,338,400.00 | |
| May 17, 2024 | Director | 1,106 | $141.90 | Sell | $156,941.40 | |
| May 15, 2024 | CFO | 15,000 | $140.24 | Sell | $2,103,600.00 | |
| May 14, 2024 | Director | 12,500 | $135.63 | Sell | $1,695,375.00 | |
| May 6, 2024 | Insider | 273 | $140.55 | Sell | $38,370.15 | |
| April 15, 2024 | Insider | 19,818 | $133.36 | Sell | $2,642,928.48 | |
| March 21, 2024 | Insider | 5,000 | $145.06 | Sell | $725,300.00 | |
| March 14, 2024 | Director | 40,000 | $139.42 | Sell | $5,576,800.00 | |
| March 14, 2024 | Insider | 75,000 | $139.38 | Sell | $10,453,500.00 | |
| March 11, 2024 | Insider | 200 | $140.00 | Sell | $28,000.00 | |
| March 11, 2024 | Director | 100 | $140.00 | Sell | $14,000.00 | |
| March 8, 2024 | Director | 1,700 | $140.05 | Sell | $238,085.00 | |
| March 8, 2024 | Insider | 1,800 | $140.03 | Sell | $252,054.00 | |
| Feb. 29, 2024 | Insider | 273 | $135.51 | Sell | $36,994.23 | |
| Feb. 27, 2024 | Director | 8,000 | $135.67 | Sell | $1,085,360.00 | |
| Feb. 20, 2024 | Director | 15,000 | $132.47 | Sell | $1,987,050.00 | |
| Feb. 13, 2024 | Insider | 1,114 | $132.96 | Sell | $148,117.44 | |
| Feb. 13, 2024 | CEO | 2,832 | $133.02 | Sell | $376,712.64 | |
| Feb. 13, 2024 | CFO | 1,352 | $132.85 | Sell | $179,613.20 | |
| Feb. 8, 2024 | CEO | 2,274 | $134.15 | Sell | $305,057.10 | |
| Feb. 8, 2024 | Insider | 1,328 | $135.41 | Sell | $179,824.48 | |
| Feb. 8, 2024 | CFO | 980 | $134.21 | Sell | $131,525.80 | |
| Feb. 6, 2024 | CFO | 1,280 | $142.19 | Sell | $182,003.20 | |
| Feb. 6, 2024 | Insider | 456 | $141.96 | Sell | $64,733.76 | |
| Feb. 6, 2024 | CEO | 3,040 | $142.18 | Sell | $432,227.20 |
Insiders are both buying and selling Neurocrine Biosciences Inc stock.
The insider traders at Neurocrine Biosciences Inc are: Kevin Charles Gorman, Gary A Lyons, Darin Lippoldt, Haig P Bozigian, Dimitri E Grigoriadis, Matt Abernethy, Christopher Flint Obrien, Eiry Roberts, Eric Benevich, Timothy P Coughlin, Kyle Gano, Julie Cooke, Ingrid Delaet, Malcolm Lloyd-Smith, William H Rastetter, Richard F Pops, David W Boyer, Stephen A Sherwin, W Thomas Mitchell, Timothy Coughlin, Corinne H Nevinny, Jude Onyia, Haig Bozigian, Dimitri Grigoriadis, Neurocrine Biosciences Inc, Shalini Sharp, Leslie V. Norwalk, Dimitri E. Grigoriadis, Gary A. Lyons, George J. Morrow, and Haig P. Bozigian
The most active insider trader at Neurocrine Biosciences Inc is Kevin Charles Gorman with 45 trades.
Kevin Charles Gorman has sold the most Neurocrine Biosciences Inc stock with a total value of $122,380,811.88.
Neurocrine Biosciences Inc has bought the most Neurocrine Biosciences Inc stock with a total value of $78,065,642.88.
The most recent insider trade for Neurocrine Biosciences Inc was on Feb. 13, 2025.
The single biggest insider buy for Neurocrine Biosciences Inc was from Neurocrine Biosciences Inc with a total value of $39,032,821.44 on Feb. 23, 2023.
The single biggest insider sell for Neurocrine Biosciences Inc was from Kevin Charles Gorman with a total value of $33,975,315.00 on Jan. 8, 2021.